Pregnancy — Prenatal Inflammation and Perinatal Outcomes
Citation(s)
Breymann C, Zimmermann R, Huch R, Huch A Use of recombinant human erythropoietin in combination with parenteral iron in the treatment of postpartum anaemia. Eur J Clin Invest. 1996 Feb;26(2):123-30.
Christian LM, Porter K Longitudinal changes in serum proinflammatory markers across pregnancy and postpartum: effects of maternal body mass index. Cytokine. 2014 Dec;70(2):134-40. doi: 10.1016/j.cyto.2014.06.018. Epub 2014 Jul 28.
Cicarelli LM, Perroni AG, Zugaib M, de Albuquerque PB, Campa A Maternal and cord blood levels of serum amyloid A, C-reactive protein, tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 during and after delivery. Mediators Inflamm. 2005 Jun 9;2005(2):96-100.
Cohen Y, Ascher-Landsberg J, Cohen A, Lessing JB, Grisaru D The role of C-reactive protein measurement as a diagnostic aid in early pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014 May;176:64-7. doi: 10.1016/j.ejogrb.2014.03.004. Epub 2014 Mar 12.
Coussons-Read ME, Okun ML, Nettles CD Psychosocial stress increases inflammatory markers and alters cytokine production across pregnancy. Brain Behav Immun. 2007 Mar;21(3):343-50. Epub 2006 Oct 6.
De Meeus JB, Pourrat O, Gombert J, Magnin G C-reactive protein levels at the onset of labour and at day 3 post-partum in normal pregnancy. Clin Exp Obstet Gynecol. 1998;25(1-2):9-11.
Derzsy Z, Prohászka Z, Rigó J Jr, Füst G, Molvarec A Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol. 2010 Apr;47(7-8):1500-6. doi: 10.1016/j.molimm.2010.01.021. Epub 2010 Feb 23.
Deveci K, Sogut E, Evliyaoglu O, Duras N Pregnancy-associated plasma protein-A and C-reactive protein levels in pre-eclamptic and normotensive pregnant women at third trimester. J Obstet Gynaecol Res. 2009 Feb;35(1):94-8. doi: 10.1111/j.1447-0756.2008.00835.x.
Ghosh TK, Ghosh S, Bhattacharjee D 2011. C-reactive protein levels in women with pregnancy induced hypertension. Bangladesh Journal of Medical Science 10:159-162.
Hwang HS, Kwon JY, Kim MA, Park YW, Kim YH Maternal serum highly sensitive C-reactive protein in normal pregnancy and pre-eclampsia. Int J Gynaecol Obstet. 2007 Aug;98(2):105-9. Epub 2007 Jun 22.
Lohsoonthorn V, Qiu C, Williams MA Maternal serum C-reactive protein concentrations in early pregnancy and subsequent risk of preterm delivery. Clin Biochem. 2007 Mar;40(5-6):330-5. Epub 2007 Jan 5.
McDade TW, Metzger MW, Chyu L, Duncan GJ, Garfield C, Adam EK Long-term effects of birth weight and breastfeeding duration on inflammation in early adulthood. Proc Biol Sci. 2014 Apr 23;281(1784):20133116. doi: 10.1098/rspb.2013.3116. Print 2014 Jun 7.
McDade TW, Williams S, Snodgrass JJ What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography. 2007 Nov;44(4):899-925. Review.
McLachlan KA, O'Neal D, Jenkins A, Alford FP Do adiponectin, TNFalpha, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab Res Rev. 2006 Mar-Apr;22(2):131-8.
Ustün Y, Engin-Ustün Y, Kamaci M Association of fibrinogen and C-reactive protein with severity of preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):154-8.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.